News
Insights from the 5-year follow-up of CTL019 in CLL
Photo courtesy of the University of Pennsylvania NEW YORK—The 5-year follow-up of the phase 1 trial of CTL019 in relapsed or refractory chronic...
News
CAR T-cell therapy tested in Sweden
NEW YORK—For the first time, according to researchers, chimeric antigen receptor (CAR) T-cell therapy has been tested in a clinical trial in...
News
Novel mAb targeting CD70 shows activity in TCL
Photo by Linda Bartlett LUGANO—The defucosylated monoclonal antibody (mAb) ARGX-110, which is active against CD70-bearing tumor cells and CD70-...
News
Novel SYK inhibitor shows ‘good early evidence’ of activity
LUGANO—The phase 1, first-in-human study of the novel SYK inhibitor TAK-659 is showing “good early evidence” of antitumor activity in patients...
News
HSCT outcomes ‘encouraging’ in JAKi responders
Photo by Chad McNeeley VIENNA—Outcomes of hematopoietic stem cell transplant (HSCT) are encouraging in myelofibrosis (MF) patients who respond...
News
PI3Kδ/γ inhibitor generates rapid responses in CLL
VIENNA—New research indicates that duvelisib, a dual inhibitor of PI3Kδ and PI3Kγ, can generate rapid partial responses in treatment-naïve...
News
Team endorses intensified chemo for PET-positive HL
Photo by Rhoda Baer LUGANO—Long-awaited results of the Intergroup H10 trial in PET-positive Hodgkin lymphoma (HL) patients have shown that...
News
‘Radically different’ PI3Kδ inhibitor lacks hepatotoxicity
Photo by Larry Young LUGANO—Updated phase 1 results with TGR-1202 suggest this next-generation PI3kδ inhibitor lacks the hepatotoxicity associated...
News
Nivolumab produces ‘dramatic’ responses in HL
Photo courtesy of UCLA LUGANO—The PD-1 checkpoint inhibitor nivolumab produces rapid, durable, and, in some cases, “dramatic” responses in...
News
Thiotepa, rituximab improve response in CNS lymphoma
site of 13-ICML LUGANO—Adding thiotepa and rituximab to the treatment of primary central nervous system (CNS) lymphoma is feasible from a safety...
News
Bleomycin can be safely omitted after negative PET2 in HL
Photo by Jens Maus LUGANO—Results of the RATHL trial indicate that bleomycin can be omitted from ABVD therapy following a negative interim FDG-...
News
Activin receptors continue to show efficacy in ß-thalassemia
Congress of the European Hematology Association VIENNA—Two very similar activin receptors, luspatercept and sotatercept, continue to show...
News
Drug won’t advance to phase 3 in ß-thalassemia
thalassemia VIENNA—Data from a phase 2a trial suggest the activin receptor sotatercept can effectively treat patients with ß-thalassemia....
News
Unsickling red blood cells
VIENNA—Researchers say they have found a way to unsickle red blood cells (RBCs), at least in vitro. Using pegylated carboxyhemoglobin bovine gas...
News
Older patients benefit from brentuximab treatment
Credit: NIH SAN FRANCISCO—Younger patients with Hodgkin lymphoma fare well on brentuximab vedotin, experiencing an overall objective response...